Contact
 

Science Speaks HIV and TB News yesterday published a Q&A with Louis Picker, associate director of the Oregon Health & Science University’s Vaccine and Gene Therapy Institute (VGTI). Picker led a team of researchers that tested in nonhuman...

Bill Gates, co-chair of the Bill and Melinda Gates Foundation, spoke to the World Health Assembly and representatives of 193 member states yesterday about vaccines, according to the Humanosphere blog. Gates called upon those in attendance and...

The World Today interviews Dr. Seth Berkeley about recent developments in HIV vaccine research.  Listen to and read the full interview here.

The HIV Prevention Trials Network (HPTN) announced findings from HPTN 052, a study to evaluate the immediate versus delayed use of antiretroviral therapy by HIV-infected individuals on transmission to uninfected partners and health of the...

A research team led by Dr. Louis Picker at Oregon Health & Science University’s (OHSU) Vaccine and Gene Therapy Institute published findings in Nature that produced a vaccine candidate that programs the immune system of non-human primates to...

Following a scheduled interim review of data from the FEM-PrEP study of oral pre-exposure prophylaxis (PrEP) using daily TDF/FTC (brand-name Truvada), the Independent Data Monitoring Committee (IDMC) advised that the FEM-PrEP study will...

Europrise News - April 13, 2011

Europrise distributed its newsletter, see below to access the full newsletter.

The French National Agency for Research on AIDS and viral hepatitis (ANRS) and the University of Paris Est announce the creation of the Vaccine Research Institute (VRI), whose mission is to  conduct research to develop a vaccine against...

The Global HIV Vaccine Enterprise and the OCTAVE Project (Online Collaborative Training for AIDS Vaccine Evaluation), are accepting applications for a new workshop focused on adjuvants and their critical role in enhancing vaccine immunogenicity...

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account